BioSpace News Archive

Jnana Therapeutics, a biotechnology company utilizing its next generation chemoproteomic platform to address well-validated but hard-to-drug targets, today announced that it has selected JNT-517 as a development candidate and a potential first-in-class oral approach for the treatment of phenylketonuria (PKU), a rare inherited metabolic disease.

Agilent Technologies Inc. (NYSE: A) announced today that researchers from the QIMR Berghofer Medical Research Institute in Brisbane, Australia, collaborated with Agilent experts on a proof-of-concept FTIR-based saliva COVID-19 testing workflow using the Agilent Cary 630 FTIR Spectrometer.

Nascent Biotech, Inc. is pleased to announce that the Company has received a payment totaling USD $750,000 from BioRay Pharmaceutical, Ltd.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in a Phase 3 clinical trial (OPTIC-J) in Japan evaluating teprotumumab for the treatment of active TED.

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company’s fourth quarter and full year 2021 financial results will be released after market close on Tuesday, March 1, 2022.

Stryker (NYSE: SYK) announced today that it has completed the previously announced acquisition of Vocera Communications, Inc. (NYSE: VCRA), a leader in digital care coordination and communication.

ARGEN-LT delivers the only continuous stability measurement for shelf-life studies at low temperature(s).

Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its full year 2021 financial results after market close on Thursday, March 10, 2022.

SINTX Technologies, Inc. (www.sintx.com) (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer (OEM) of advanced ceramics, announced new results on the development of manufacturing technologies to produce fabrics impregnated with SINTX silicon nitride, and the antipathogenic testing of these fabrics.

IgGenix, Inc., a biotechnology company taking a revolutionary approach to directly alleviate allergic disease, today announced a featured poster presentation at the upcoming the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting to be held February 25-28, 2022, in Phoenix, Ariz.